Furthermore, Choi et al. 34 demonstrated that α-mangostin (50 mg/kg) administered for 5 weeks could decrease hepatic steatosis, fat mass accumulation and BW through regulating lipid metabolism via the SIRT1-adenosine monophosphate-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor γ (PPARγ) pathways in mice with HFD-induced obesity. Here, PPARG is linked to Hepatic steatosis.